NCT03915964已完成4 期
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 2,659
- 试验地点
- 507
- 主要终点
- Time from First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE)
研究概览
简要总结
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have at least one of the following characteristics:
- •Documented evidence of a VTE prior to this study
- •At least 60 years of age
- •A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or
- •Age 50 to less than 60 years and BMI 25 to less than 30 kg/m².
- •Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drug (DMARD) (synthetic or biologic).
排除标准
- •Participant should have no reason to not take a TNF inhibitor.
- •Participants must not be pregnant or breastfeeding.
- •Participants must not have had more than one VTE.
- •Participants must not have cancer.
- •Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness.
- •Participants must not have had a live vaccine within four weeks of study start.
- •Participants must not have participated in any other clinical trial within four weeks of study start.
- •Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year.
研究组 & 干预措施
Baricitinib Low Dose
Experimental
Baricitinib administered orally.
干预措施: Baricitinib (Drug)
Baricitinib High Dose
Experimental
Baricitinib administered orally.
干预措施: Baricitinib (Drug)
TNF Inhibitor
Active Comparator
Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
干预措施: TNF Inhibitor (Drug)
结局指标
主要结局
Time from First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE)
时间窗: Baseline through Study Completion (Approximately 5.5 Years)
Time from First Dose of Study Treatment to First Event of VTE
次要结局
- Time from First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE)(Baseline through Study Completion (Approximately 5.5 Years))
- Time from First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE)(Baseline through Study Completion (Approximately 5.5 Years))
- Time from First Dose of Study Treatment to First Malignancy (excluding nonmelanoma skin cancer [NMSC])(Baseline through Study Completion (Approximately 5.5 Years))
- Time from First Dose of Study Treatment to First Opportunistic Infection(Baseline through Study Completion (Approximately 5.5 Years))
- Time from First Dose of Study Treatment to First Serious Infection(Baseline through Study Completion (Approximately 5.5 Years))
研究者
研究点 (507)
Loading locations...
相似试验
已完成
4 期
A Study of Baricitinib in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT04086745Eli Lilly and Company1,050
已完成
3 期
A Study in Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT01710358Eli Lilly and Company1,307
尚未招募
2 期
Baricitinib for the Lung Injury Following Spontaneous SAHSpontaneous Subarachnoid HemorrhageNCT06439615Tang-Du Hospital100
已完成
3 期
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)Systemic Lupus ErythematosusNCT03616964Eli Lilly and Company778
终止
3 期
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT03616912Eli Lilly and Company830